Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose ...

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

U.S. Health Secretary Robert F. Kennedy Jr’s newly appointed Advisory Committee on Immunization Practices (ACIP) upheld ...

At first, the monovalent influenza A (H5N8) vaccine will be tested in two doses, 21 days apart, in adults aged 18–59.